MedTrace Logo

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

NCT06140407 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-06-05

No results posted yet for this study

Summary

This phase II trial studies how well pembrolizumab after standard treatment with radiation plus the following chemotherapy drugs: cisplatin or carboplatin, plus etoposide works in treating patients with limited stage small cell lung cancer (LS-SCLC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after standard treatment with radiation plus chemotherapy may increase the ability of the immune system to fight LS-SCLC.

Conditions

  • Limited Stage Lung Small Cell Carcinoma
  • Stage I Lung Cancer
  • Stage II Lung Cancer
  • Stage III Lung Cancer

Interventions

DRUG

Cisplatin

Receive Cisplatin

DRUG

Carboplatin

Receive Carboplatin

DRUG

Etoposide

Receive Etoposide

BIOLOGICAL

Pembrolizumab

Receive Pembrolizumab by IV

PROCEDURE

Computed Tomography

Undergo Computed Tomography

PROCEDURE

Positron Emission Tomography

Undergo Positron Emission Tomography

PROCEDURE

Magnetic Resonance Imaging

Undergo Magnetic Resonance Imaging

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

RADIATION

Radiation Therapy

Undergo Radiation Therapy

Sponsors & Collaborators

Principal Investigators

  • Ryan Whitaker, MD, PhD · Vanderbilt University/Ingram Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-14
Primary Completion
2025-05-27
Completion
2025-05-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06140407 on ClinicalTrials.gov